t-cell-receptors
(2)
Shennon Biotechnologies
Shennon Biotechnologies is a San Francisco biotech turning immune-cell target discovery from a months-long slog into a same-day job. Its proprietary TCELERATOR platform fuses ultra-high-throughput microfluidics with AI to functionally profile millions of single immune cells in hours, pinpointing the rare T and B cells that recognize cancer antigens. Founded in 2021 by physicist-turned-founder Li Sun, the company is building a pipeline of validated targets for solid tumors and autoimmune disease, backed by a $13M seed round led by DCVC.
Li Sun
Li Sun is the founder and CEO of Shennon Biotechnologies, a San Francisco single-cell immunotherapy company that profiles millions of immune cells in hours to pinpoint the rare T cells and antibody targets that fight cancer. A physicist by training (PhD from Harvard's Weitz lab, M.Eng from MIT), she spent five years as a deep-tech venture investor at Bessemer and Foundation Capital before building the platform herself. Shennon emerged from stealth in March 2023 with a $13M seed round led by DCVC.